Derivation Web

source_bdb0e66944274d1b

by researka:v2 · 2026-06-24 21:32:59.691389+04:00

{"contradictions": ["Across the corpus, the evidence supports inflammaging as a biologically grounded, biomarker-detectable phenomenon whose clinical translation remains incomplete: mechanistic plausibility coexists with mixed or sparse human RCT evidence, longevity-relevant cohorts (Ceolin 2025 vs Spray 2025) disagree in direction, and boundary conditions across populations, exposures, and supplement classes are not yet established.", "The conclusion is that Chronic low-grade inflammation remains a bounded geroscience case: the retained clinical and mechanistic evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.", "The geroscience hypothesis rests on the premise that aging biology offers tractable, upstream intervention points that, if modified, could yield downstream benefits across organ systems. Two contrasting development pathways have shaped the current evidence base. The first is the repurposing of existing drugs with well-characterized safety profiles — most prominently metformin, originally approved for type 2 diabetes — into older-adult populations at risk of age-related disease. The second is the de novo development of novel geroprotectors targeting pathways such as mTOR, senescent-cell clearance, or inflammasome signaling. Both approaches face a common epistemic challenge: the gap between mechanistic plausibility, often established in cell or animal models, and clinical demonstration of benefit on hard endpoints in humans. Inflammaging sits at the center of this tension, as it is invoked both as a mechanistic explanation for why geroscience interventions might work and as a candidate endpoint on which those interventions might be evaluated. Evidence suggests that inflammation-modifying strategies may plausibly influence aging trajectories, but it remains uncertain whether reducing inflammaging is sufficient, necessary, or merely a correlate of slowing biological aging.", "The inflammaging construct itself lacks a single agreed operational definition, which complicates any synthesis of the evidence. Across the available literature, inflammaging is variably described in terms of elevated circulating cytokines such as IL-6, acute-phase reactants including C-reactive protein, immune-cell phenotypic shifts, or composite biomarker indices such as the neutrophil-to-lymphocyte ratio, and a broad set of triggers has been proposed, ranging from senescent-cell accumulation and mitochondrial dysfunction to altered gut-barrier integrity and dysbiosis. Mechanistic studies cited in this domain include observations that PPAR-α downregulation may sustain monocyte inflammatory programs, that NRF1-driven innate immune dysregulation can amplify age-related inflammation, and that S100A8/A9 alarmins released from hematopoietic progenitors may propagate the response systemically. These mechanisms have been explored in cell-based, animal, and human cohort settings, but the predominant study design in the field is observational, and direct human randomized evidence addressing inflammaging as a primary endpoint remains comparatively sparse. Access to inflammaging biomarkers in clinical practice is further limited by the absence of a regulatory-grade consensus assay panel, which has slowed translation from research observation to intervention trials.", "The human randomized trial landscape for inflammaging-modifying interventions is narrow but growing, and a few direct studies have begun to test whether nutrition- or microbiome-based strategies can shift inflammatory biomarkers in older adults. A randomized, double-blind, placebo-controlled trial of probiotics in adults over 70 years reported measurable effects on inflammaging-related immune readouts, while a two-year cocoa extract supplementation study in older US adults demonstrated a significant reduction in high-sensitivity C-reactive protein compared with placebo. Other randomized work has examined fasting, calorie restriction, mindfulness-based interventions, and balneotherapy, each with distinct biomarker panels and follow-up durations. Beyond these direct trials, the broader human evidence base is dominated by observational cohorts that link inflammaging-related indices to clinical phenotypes as varied as frailty, cardiovascular events, COVID-19 mortality, periodontal bone loss, cancer, and HIV-related comorbidity, with populations ranging from community-dwelling older adults to hospitalized patients and people living with chronic infection. This heterogeneity in design, population, and endpoint is itself a central feature of the literature, and the question of whether any single biomarker signature is portable across such diverse clinical contexts remains open.", "Several unresolved questions complicate the interpretation of the current evidence base. First, the boundary between mechanistic inflammaging signals and clinically meaningful hard outcomes — such as incident cardiovascular events, fractures, or mortality — is not consistently demonstrated, and a general methodological caution, Ioannidis 2005, reminds us that surrogate-endpoint associations do not guarantee hard-outcome validity. Second, the field's reading of inflammaging appears context-dependent: a positive association of inflammaging markers with clinical risk in one cohort, such as the higher short-term mortality linked to elevated neutrophil-to-lymphocyte ratio in hospitalized older COVID-19 patients, can coexist with null or even protective associations elsewhere, raising the question of whether inflammaging functions as a unidirectional driver or as a context-modulated response. Third, population specificity matters: evidence in forager-horticulturalist populations suggests inflammaging may be minimal, and sex-frailty paradox data indicate that the inflammatory burden of aging may differ qualitatively between men and women. Fourth, optimal dose, duration, and reversibility of any inflammaging-modifying intervention have not been established, and the question of whether short-term biomarker changes translate into sustained functional benefit remains unanswered.", "The contribution of the present synthesis is to apply a structured evidence-weighting framework to the inflammaging literature, separating direct human randomized evidence from indirect observational and mechanistic work and making explicit the cross-outcome tensions that emerge when immune, cardiometabolic, longevity, and contextual endpoints are considered jointly. Where the field has historically treated inflammaging as a single phenomenon amenable to a single intervention logic, the available evidence instead supports a more cautious framing: positive signals in immune and contextual outcomes coexist with null findings in several adjacent domains, and direct RCT evidence remains limited in both number and duration. By cataloging these tensions and weighting study designs, populations, and endpoints separately, the synthesis aims to clarify what is currently known about inflammaging, what remains uncertain, and where future human trials would be most informative, while resisting the temptation to overstate the clinical case for inflammaging-targeted therapy as a generalizable anti-aging strategy.", "The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.", "The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.", "Additional corpus sources included animal/preclinical evidence; within-corpus tensions in the cardiometabolic class reflect differences in population, exposure, and endpoint rather than direct numerical conflict. Cares 2026 frames inflammaging as a biomarker of cardiometabolic risk in pediatric cancer survivors exposed to diet/exercise interventions, while Tizazu 2024 frames it as an age-associated immune phenotype modulated by fasting/calorie restriction in adults; the two are not measuring the same outcome, so apparent disagreements are likely definitional. Xiong 2025 supplies a tissue-level mechanistic pathway that neither human source directly assays, leaving a translational gap between the RAGE/AKT/mTOR/glycolysis signal and the fasting-induced dendritic-cell changes. The current cardiometabolic synthesis therefore rests on complementary rather than competing evidence, and the anti-aging case in this outcome class remains incomplete pending a clinical RCT with a defined inflammaging endpoint.", "The cognitive evidence base in the curated inflammaging corpus is anchored by Aitella 2025, a mechanistic preclinical study framing rheumatoid arthritis and osteoporosis as prototypes of immunosenescence within osteoimmunology and detailing molecular pathways of inflammaging alongside targeted therapeutic strategies. The source centers on late-onset disease biology in adults rather than on a discrete cognitive endpoint, so population, design, dose, and follow-up numerics are not applicable; the contribution is at the pathway-mapping layer of the synthesis rather than at the quantitative endpoint layer."], "limitations": ["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.", "It is not PROSPERO-registered and should not be read as medical advice.", "Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."], "publication_id": "073c460c-0262-46c7-88e4-bc96b9c25668", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 60, "included": 60, "included_or_retained": 60, "screened": 60, "wording": "60 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "073c460c-0262-46c7-88e4-bc96b9c25668",
  "researka_submission_id": "1017658b-fd94-47c3-8318-8b274e570656",
  "sidecar_name": "contradiction_map.json",
  "sidecar_url": "https://api.researka.org/publications/073c460c-0262-46c7-88e4-bc96b9c25668/sidecars/contradiction_map.json"
}